Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats

International Journal of Molecular Medicine

Volumn 22, Issue 3, 2008, Pages 317-323

  Yomogida, Shin ^a   Kojima, Yuko ^a   Tsutsumi Ishii, Yuko ^a   Hua, Jian ^a   Sakamoto, Koji ^b   Nagaoka, Isao ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Koyo Chemical Co Ltd   (Japan)

Author keywords

Dextran sulfate sodium induced colitis; Glucosamine; Inflammatory bowel diseases; Intestinal epithelial cells

Indexed keywords

DEXTRAN SULFATE; GLUCOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; BIOLOGICAL PRODUCT; CD11B ANTIGEN; CYTOKINE; MONOSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; ENTERITIS; EPITHELIUM CELL; HISTOPATHOLOGY; IN VIVO STUDY; INTESTINE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; NEUTROPHIL; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD11B; BIOLOGICAL PRODUCTS; COLITIS; CYTOKINES; DEXTRAN SULFATE; GLUCOSAMINE; MALE; MONOSACCHARIDES; NEUTROPHILS; NF-KAPPA B; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53049093337     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000025     Document Type: Article

References (33)

1. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P and Naumann M: Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease. FASEB J 18: 1550-1552, 2004.
2. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I and Marzo VD: Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570, 2006.
3. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y and Hibi T: Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol 41: 318-324, 2006.
4. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
5. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J and Luo HS: Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Mediators Inflamm 4: 185-193, 2005.
6. Crolle G and D'Este E: Glucosamine sulphate for the management of arthrosis. A controlled clinical investigation. Curr Med Res Opin 7: 104-109, 1980.
7. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162: 2113-2123, 2002.
8. McAlindo TE, LaValley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283: 1469-1475, 2000.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 357: 251-256, 2001.
10. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP and Orth MW: Glucosamine HCl reduces equine articular cartilage degradation in explants culture. Osteoarthritis Cartilage 8: 258-265, 2000.
11. Oegema TR Jr, Deloria LB, Sandy JD and Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46: 2495-2503, 2002.
12. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Giogleux F and Ouzzine M: Interleukin-16 down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis. Arthritis Rheum 44: 351-360, 2001.
13. Hua J, Sakamoto K and Nagaoka I: Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 71: 632-640, 2002.
14. Jang BC, Sung SH, Park JG, Park JW, Bae JH, Shin DH, Park GY, Han SB and Suh SI: Glucosamine-hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem 282: 27622-27632, 2007.
15. Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T and Kawahara T: Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 27: 213-218, 2007.
16. Hua J, Suguro S, Hirano S, Sakamoto K and Nagaoka I: Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 54: 127-132, 2005.
17. Yomogida S, Hua J, Sakamoto K and Nagaoka I: Glucosamine suppresses the interleukin-8 production and ICAM-1 expression by TNF-α-stimulated human colonic epithelial cell line HT-29. Int J Mol Med 22: 205-211, 2008.
18. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
19. Shichijo K, Makiyama K, Wen CY, Matsuu M, Nakayama T, Nakashima M, Ihara M and Sekine I: Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats. World J Gastroenterol 11: 4505-4510, 2005.
20. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110, 1983.
21. Cooper HS, Murthy SNS, Shah RS and Sedergran DJ: Clinico-pathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
22. Ohkawara T, Takeda H, Kato K, Miyashita K, Kato M, Iwanaga. T and Asaka M: Polaprezinc (N-(3-aminopropionyl)-L-histidinato zinc) ameliorates dextran sulfate sodium-induced colitis in mice. Scand J Gastroenterol. 40: 1321-1327, 2005.
23. Särndahl E, Bergström I, Brodin VP, Nijm J, Setterud HL and Jonasson L: Neutrophil activation status in stable coronary artery disease. PLoS ONE 2: e1056, 2007.
24. Elson CO, Sartor RB, Tennyson GS and Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
25. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA and Sedergran DJ: Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 38: 1722-1734, 1993.
26. 1 regulates intestinal inflammation in experimental colitis. J Clin Invest 110: 1773-1782, 2002.
27. Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, O'Brien M and Becker JM: NF-κB Activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 50: 2366-2378, 2005.
28. Visekruna A, Joseris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SHE, Schmidt-Ullrich R and Steinhoff U: Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 116: 3195-3203, 2006.
29. Rogler G and Andus T: Cytokine in inflammatory bowel disease. World J Surg 22: 382-389, 1998.
30. Ishiguro Y: Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 34: 66-74, 1999.
31. Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus J, Schölmerich J, Gross V and Falk W: Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358, 1997.
32. Rogler G and Andus T: Cytokines in inflammatory bowel disease. World J Surg 22: 392-389, 1998.
33. Dallegri F and Ottonello L: Tissue injury in neutrophilic inflammation. Inflamm Res 46: 382-391, 1997.